Having trouble accessing articles? Reset your cache.

Abiraterone extends overall survival in CRPC

Johnson & Johnson (NYSE:JNJ) said once-daily abiraterone plus twice-daily predinose/prednisolone significantly improved overall survival by

Read the full 159 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury

SIGN UP

Article Purchase

This article may not be distributed to non-subscribers
More Info >PURCHASE